Soper J W, Chaturvedi A K, Canfield D V
Toxicology and Accident Research Laboratory, Aeromedical Research Division, Civil Aeromedical Institute, Federal Aviation Administration, U.S. Department of Transportation, Oklahoma City, OK, USA.
Aviat Space Environ Med. 2000 Dec;71(12):1206-9.
Chlorpheniramine is known to cause drowsiness, and this side effect has a potential to impair performance and could be a factor in accidents.
Therefore, to establish the prevalence of this drug in pilot fatalities of aviation accidents, a postmortem toxicology database--maintained at the Civil Aeromedical Institute--was examined for the presence of chlorpheniramine in the fatalities, occurred during 1991-1996.
There were 47 (2.2%) accidents involving chlorpheniramine. Of these, 16 had only chlorpheniramine at 109 ng.ml-1 (n = 4) in blood and 1412 ng.g-1 (n = 12) in liver. Other drugs were also present in the remaining 31 cases, wherein chlorpheniramine concentrations were 93 ng.ml-1 (n = 18) in blood and 747 ng.g-1 (n = 12) in liver. Ninety-five percent of all quantitated blood values were at or above the therapeutic level (10 ng.ml-1), giving a 100 ng.ml-1 (n = 21) mean blood value. The drug's mean liver concentration from all cases was 1080 ng.g-1 (n = 24). The average blood value was approximately 10 times higher than the therapeutic value.
The presence of other drugs did not appear to significantly alter the blood chlorpheniramine level, but no such correlation could be established with the hepatic value. The approximate 10-fold increase in the liver concentration was consistent with the general trend of drug distribution in the hepatic compartment. However, the contribution of postmortem redistribution of the drug to alter its concentration cannot be entirely ruled out. This study suggests that chlorpheniramine was present in some aviation fatalities at levels higher than therapeutic levels.
已知氯苯那敏会导致嗜睡,这种副作用有可能损害行为能力,并且可能是事故发生的一个因素。
因此,为确定该药物在航空事故飞行员死亡案例中的出现频率,对民航医学研究所维护的一个死后毒理学数据库进行了检查,以查找1991年至1996年期间死亡案例中氯苯那敏的存在情况。
有47起(2.2%)事故涉及氯苯那敏。其中,16起案例血液中仅含有氯苯那敏,浓度为109纳克/毫升(n = 4),肝脏中为1412纳克/克(n = 12)。其余31起案例中还存在其他药物,其中氯苯那敏浓度血液中为93纳克/毫升(n = 18),肝脏中为747纳克/克(n = 12)。所有定量血液值的95%处于或高于治疗水平(10纳克/毫升),血液平均浓度值为100纳克/毫升(n = 21)。所有案例中该药物的肝脏平均浓度为1080纳克/克(n = 24)。平均血液浓度值约比治疗值高10倍。
其他药物的存在似乎并未显著改变血液中氯苯那敏的水平,但无法确定与肝脏浓度值之间存在此类关联。肝脏浓度大约增加10倍与药物在肝脏部位的分布总体趋势一致。然而,不能完全排除药物死后再分布对其浓度变化的影响。本研究表明,在一些航空事故死亡案例中,氯苯那敏的含量高于治疗水平。